mobile-logo

Author: 16by9

03 Feb

Webinars are now accessible online

by 16by9
in Other News
Comments

If you missed any of our past webinars, you can now view them online! Under the Publications menu, you can now find a new Webinars section. If you have further questions about our services or products, please contact us using this form or directly at info@physiomics-plc.com....

Read More
11 Nov

Final Results for the year ended 30 June 2015

by 16by9
in Investor News / RNS
Comments

Chairman's Statement  Summary of Results in the year ended 30 June 2015 •    The turnover of the Company was £235,486 (2014: £267,903). •    The operating loss reduced to £414,755 (2014: £465,265). •    On 30 June 2015 the surplus of shareholders' funds was £325,617 (2014: £136,487). This year, Physiomics extended its product range and made a key commercial breakthrough, signing its first long term Virtual Tumour Clinical deal with a large pharmaceutical company. In summary...

Read More
06 Nov

Strategic Update

by 16by9
in Investor News / RNS
Comments

Physiomics is pleased to provide an update on its strategic direction. For some time the Company has been pursuing M&A targets, in particular oncology therapeutics companies that could benefit from the application of Virtual Tumour and other PYC modelling tools. Physiomics has now identified a number of potential targets, including one in particular where the synergy with our modelling skills is strong....

Read More
05 Aug

Professor Mark Middleton appointed to Physiomics SAB

by 16by9
in Other News
Comments

Physiomics plc is pleased to announce that it has appointed Professor Mark Middleton to its Scientific Advisory Board. Professor Middleton is Professor of Experimental Cancer Medicine in the Department of Oncology of the University of Oxford. He is an eminent clinician with highly relevant clinical experience. Mark is the Lead Cancer Clinician for the Oxford University Hospitals NHS Trust and deputy director of the Cancer Research...

Read More
28 Apr

Workshop on Applications of Physiomics’ Virtual Tumour to Immunotherapy and Translational Science- June 2, 2015, Hersonissos (Greece)

by 16by9
in Investor News / RNS
Comments

Physiomics will present a half-day workshop on “Applications of Physiomics’ Virtual Tumour to Immunotherapy and Translational Science”, ahead of the 2015 PAGE meeting. This workshop will review the preclinical Virtual Tumour model used to predict optimal doses and schedules of combination therapy. We will provide an overview regarding the recent extension of the current model to include immunotherapy and clinical translational. This will then be...

Read More
22 Apr

Physiomics to present new developments of the Virtual Tumour platform in immunotherapy at AACR Annual Meeting 2015

by 16by9
in Other News
Comments

Physiomics plc is pleased to announce that it is participating in the American Association for Cancer Research Annual Meeting 2015, taking place at the Pennsylvania Convention Center, Philadelphia, Pennsylvania on 18-22 April 2015. Dr Frances Brightman will present on the application of the Virtual Tumour platform to predict agents targeting the PD-1/PD-L1 axis in combination with radiotherapy. ...

Read More